Diagnostic Enzyme Market Report 2026

The diagnostic enzyme market size has grown strongly in recent years. It will grow from $4.49 billion in 2025 to $4.75 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to limited availability of high-purity diagnostic enzymes, reliance on traditional assay methods, increasing prevalence of chronic diseases, growing biotechnology and research initiatives, rising awareness of enzyme-based diagnostics.

The diagnostic enzyme market size is expected to see strong growth in the next few years. It will grow to $6.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to development of advanced enzyme engineering techniques, integration of diagnostics with digital health platforms, rising adoption of point-of-care testing, expansion of pharmaceutical and biotech R&D, increasing government and private funding for diagnostic innovations. Major trends in the forecast period include rising adoption of enzyme-based diagnostic kits, growth in personalized medicine and biomarker detection, expansion of research and biotechnology applications, increasing demand for high-specificity and sensitive enzymes, integration of enzyme diagnostics in point-of-care testing.

The increasing prevalence of chronic diseases is expected to drive the growth of the diagnostic enzymes market in the coming years. Chronic diseases are long-term health conditions that persist for three months or longer. Diagnostic enzymes play a critical role in the diagnosis and ongoing monitoring of chronic diseases and other medical conditions by enabling healthcare professionals to evaluate disease severity, track treatment effectiveness, and make informed adjustments to care plans. For example, in January 2023, according to the National Library of Medicine, a US-based agency, the population in the United States aged 50 years and older with at least one chronic condition is projected to rise by 99.5%, increasing from 71.522 million to 142.66 million by 2050. Therefore, the growing burden of chronic diseases is contributing to the expansion of the diagnostic enzymes market.

Major companies operating in the diagnostic enzymes market are increasingly emphasizing technological innovations, such as digital PCR platforms, to address the rising demand for highly sensitive and absolute quantification in clinical diagnostics, particularly in oncology and infectious disease testing. Digital PCR (dPCR) is a technique that divides a sample into thousands of nanoliter-scale reactions, enabling precise absolute quantification of target nucleic acids without the need for standard curves. Unlike traditional quantitative PCR, which relies on reference standards and may lack accuracy at low target levels, dPCR delivers greater precision. For instance, in September 2024, QIAGEN N.V., a Germany-based biotechnology company, launched the QIAcuityDx Digital PCR System, a clinical-grade dPCR platform. This system combines partitioning, thermocycling, and imaging within a single automated device, allowing accurate DNA and RNA quantification for applications such as liquid biopsy-based cancer monitoring. The platform features IVDR certification in Europe, 510(k) exemption in the United States, intuitive software, flexible scheduling, and support for companion diagnostic development through the GeneGlobe platform. The QIAcuityDx system improves laboratory efficiency by reducing manual handling while delivering consistent and reliable results, even for low-abundance targets.

In January 2023, SD Biosensor Inc., a South Korea-based provider of in vitro diagnostic platforms and rapid testing systems, together with its partner SJL Services Private Limited, acquired Meridian Bioscience Inc. for $1.53 billion. Through this acquisition, SD Biosensor sought to accelerate its expansion into the US in vitro diagnostics market by leveraging Meridian Bioscience’s established regulatory expertise and distribution network. Meridian Bioscience Inc. is a US-based company specializing in diagnostic testing solutions and life-science raw materials.

Major companies operating in the diagnostic enzyme market are Sanofi S.A., Advanced Enzymes Technologies, Aldevron LLC, Amano Enzymes Inc., Codexis Inc., EKF Diagnostic, Kaneka Eurogentec, Roche Holding AG, Sekisui Diagnostics LLC, Thermo Fisher Scientific Inc., Charles River Laboratories, Biocatalysts, Merck & Co. Inc., Chr. Hansen, Kerry Group, Dyadic International, Creative Enzymes, Pfizer Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson, AbbVie Inc., Amgen Inc., Biogen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc.

North America was the largest region in the enzymes market in 2025. Middle East is expected to be the fastest-growing region in the diagnostic enzyme market report during the forecast period. The regions covered in the diagnostic enzyme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the diagnostic enzyme market by raising costs for imported high-purity enzymes, reagents, and laboratory equipment, particularly affecting segments like polymerases, nucleases, and proteases. Regions such as North America and Europe, which depend heavily on imports from Asia-Pacific manufacturing hubs, are most affected. While tariffs have increased operational costs and slowed procurement, they have also incentivized local enzyme production, development of cost-effective alternatives, and innovation in diagnostic assay technologies.

The diagnostic enzyme market research report is one of a series of new reports that provides diagnostic enzyme market statistics, including diagnostic enzyme industry global market size, regional shares, competitors with a diagnostic enzyme market share, detailed diagnostic enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic enzyme industry. This diagnostic enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diagnostic enzymes are enzymes that are used either directly or as components of assay systems to identify the presence or absence of various compounds, helping to detect, diagnose, or predict the progression of disease conditions. They are widely applied in diagnostics due to their high substrate specificity and measurable activity, even in the presence of other proteins.

The primary product types in the diagnostic enzymes market include carbohydrases, polymerases, nucleases, proteases, and others. Carbohydrases are a class of enzymes, such as amylase, that facilitate the breakdown or synthesis of carbohydrates, including disaccharides. These enzymes are sourced from animals, microorganisms, and plants and are used across applications such as biocatalysts, diagnostics, pharmaceuticals, research, and biotechnology.

The diagnostic enzymes market consists of sales of acid phosphatase, alanine aminotransferase, cholinesterase, and aspartate aminotransferase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in the diagnostic enzymes market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.